title: [Inadequate management of dyslipidaemic patients in France. Results of the Odyssée study].
abstract: The objective of this study was to compare the results of the management of dyslipidaemic patients in the community with the objectives fixed by the AFSSAPS recommendations. An observational epidemiological study was set up among 4 000 general practitioners and 527 cardiologists. This study included 22 323 patients (average age 60.6 years) affected by a documented primary dyslipidaemia. The average number of associated risk factors, according to the AFSSAPS criteria, was 1.8. The prevalence of secondary prevention in patients was 17.5%. More than 80% of patients were being treated by a lipid lowering agent (fibrate or statin) combined or not with lifestyle guidelines. In primary prevention, although the target levels of LDL-C fixed by the AFSSAPS were attained in 94.4% and 82.6% respectively for patients with no other risk factor or with one associated risk factor, the objectives were reached in only 55.4% of patients with two other risk factors and in 29.6% of patients with more than two other risk factors. In secondary prevention, the AFSSAPS objectives were attained in only 45.2% of patients. Following this lipid result, 34.8% of patients underwent therapeutic adjustment, principally the use of medication in the patients receiving lifestyle advice or reinforcement of pharmacological treatment. This study underlines the inadequate management in France of dyslipidaemic patients in the community.
authors.affiliation: Service de cardiologie B, Unité de prévention de l'athérosclérose, CHU Rangueil, Toulouse 9. ferrieres.j@chu-toulouse.fr
authors.forename: J
authors.initials: J
authors.lastname: Ferrières
authors.forename: M
authors.initials: M
authors.lastname: Elbaz
authors.forename: E
authors.initials: E
authors.lastname: Maupas
authors.forename: D
authors.initials: D
authors.lastname: Carriè
authors.forename: J
authors.initials: J
authors.lastname: Puel
mesh_terms: D000328:Adult; D000368:Aged; D002309:Cardiology; D019090:Case Management / Q000592:standards*; D003131:Combined Modality Therapy; D003327:Coronary Disease / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D004363:Drug Utilization; D005194:Family Practice; D005260:Female; D005602:France / Q000453:epidemiology; D006306:Health Surveys; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000150:complications / Q000178:diet therapy / Q000188:drug therapy / Q000453:epidemiology / Q000628:therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008019:Life Style; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D012189:Retrospective Studies; D012307:Risk Factors; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D000960:Hypolipidemic Agents; D008055:Lipids